Boston – October 11, 2016 – Cooley advised Charles River Laboratories on its acquisition of Agilux Laboratories for $64 million.
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions accelerate their research and drug development efforts. Agilux is a contract research organization that provides a suite of integrated discovery small and large molecule bioanalytical services, drug metabolism and pharmacokinetic services and pharmacology services.
“Agilux reinforces the linkage between our discovery and safety assessment capabilities, and provides clients with a comprehensive testing solution that spans their discovery and regulated drug development needs,” said James Foster, CEO of Charles River in a company press release.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900 lawyers across 12 offices in the United States, China and Europe.